Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma.
Nairismägi M-, Gerritsen ME, Li ZM, Wijaya GC, Chia BKH, Laurensia Y, Lim JQ, Yeoh KW, Yao XS, Pang WL, Bisconte A, Hill RJ, Bradshaw JM, Huang D, Song TLL, Ng CCY, Rajasegaran V, Tang T, Tang QQ, Xia XJ, Kang TB, Teh BT, Lim ST, Ong CK, Tan J.
Nairismägi M-, et al. Among authors: tang t, tang qq.
Leukemia. 2018 May;32(5):1147-1156. doi: 10.1038/s41375-017-0004-x. Epub 2018 Feb 2.
Leukemia. 2018.
PMID: 29434279
Free PMC article.